AgingResearch.NewsJoin free

Kyverna Therapeutics

CompanyUnited States

RORWikidata

Kyverna Therapeutics develops one asset, in phase 2 (KYSA-8 in stiff person syndrome). Mostly cell therapy acting on CD19; based in the United States.

1
Asset
Furthest stage
Phase 2
5
Trials
0
Signals

Pipeline

1

  • KYSA-8

    Autologous CD19-directed chimeric antigen receptor (CAR) T-cell therapy depleting B cells.

    Phase 2, Cell therapy, CD19, stiff person syndrome, progressive multiple sclerosis (Human trials)

Full company profiles: pipeline, trials, funding and people.

See Pro

In the full profile

  • Evidence behind the mechanisms1
  • Trials6
  • Similar companies6

Intelligence